1. Home
  2. TENX vs EVC Comparison

TENX vs EVC Comparison

Compare TENX & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$15.72

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

HOLD

Current Price

$10.85

Market Cap

335.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
EVC
Founded
1967
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
317.8M
335.0M
IPO Year
2001
2000

Fundamental Metrics

Financial Performance
Metric
TENX
EVC
Price
$15.72
$10.85
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
1.4M
2.0M
Earning Date
05-15-2026
05-05-2026
Dividend Yield
N/A
5.35%
EPS Growth
N/A
47.59
EPS
N/A
0.13
Revenue
N/A
$536,034,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$84.69
Revenue Growth
N/A
N/A
52 Week Low
$5.80
$1.95
52 Week High
$19.40
$13.74

Technical Indicators

Market Signals
Indicator
TENX
EVC
Relative Strength Index (RSI) 54.93 49.16
Support Level $12.84 $2.75
Resistance Level $16.35 $13.74
Average True Range (ATR) 1.28 0.80
MACD -0.17 -0.30
Stochastic Oscillator 36.73 20.33

Price Performance

Historical Comparison
TENX
EVC

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: